

# Case Report Section

Paper co-edited with the European LeukemiaNet

## Translocation t(5;6)(q33-34;q23) in an acute myelomonocytic leukemia patient

Adriana Zamecnikova, Soad Al Bahar, Ramesh Pandita

Kuwait Cancer Control Center, Department of Hematology, Laboratory of Cancer Genetics, Kuwait (AZ, SA, RP)

Published in Atlas Database: February 2014

Online updated version : <http://AtlasGeneticsOncology.org/Reports/t0506q33q23ZamecID100076.html>  
DOI: 10.4267/2042/54042This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.  
© 2014 Atlas of Genetics and Cytogenetics in Oncology and Haematology

### Abstract

Case report and literature review on translocation t(5;6)(q33-34;q23) in an acute myelomonocytic leukemia patient.

### Clinics

**Age and sex**

68 years old female patient.

**Previous history**

No preleukemia, no previous malignancy, no inborn condition of note, no main items.

**Organomegaly**

No hepatomegaly, no splenomegaly, no enlarged lymph nodes, no central nervous system involvement.

### Blood

**WBC:** 104 X 10<sup>9</sup>/l**HB:** 7.8g/dl**Platelets:** 57 X 10<sup>9</sup>/l**Blasts:** 84%**Bone marrow:** Hypercellular marrow with 87% blasts which were PAS diffuse granular positive and SBB (Sudan Black B) positive.

### Cyto-Pathology Classification

**Cytology**

Acute myelomonocytic leukemia

**Immunophenotype**

Positive for CD13, CD15, CD117, CD33, MPO, CD45, HLDR and dim CD34 (27%)

**Diagnosis**

Acute myelomonocytic leukemia

### Survival

**Date of diagnosis:** 03-2013**Treatment:** Chemotherapy (Daunorubicin & Cytarabine combination therapy; consolidation with high dose Ara-C)**Complete remission:** no**Treatment related death:** no**Relapse:** yes**Phenotype at relapse:** Acute myelomonocytic leukemia**Status:** Lost**Last follow up:** 11-2013**Survival:** 8 months


### Karyotype

**Sample:** Bone marrow, blood**Culture time:** 24h**Banding:** G-banding**Results**

46,XX,t(5;6)(q33-34;q23)[25]

**Karyotype at Relapse**

46,XX,t(5;6)(q33-34;q23)[1]/46,XX,t(5;6)(q33-34;q23),t(7;10)(p22;q23)[19]



**Figure 1.** **A.** Karyotype from the time of diagnosis showing the chromosomal translocation  $t(5;6)(q33-34;q23)$ . **B.** Fluorescence in situ hybridization studies (FISH) with XL 6q21/6q23 (Metasystem, Germany) probe showing red and green signals on both, normal and der(6) chromosomes. **C.** Applying the XL PDGFR probe (Metasystem, Germany) showed normal signal pattern on both normal and der(5) chromosomes, indicating that PDGFR located on 5q32-33 is not involved in the translocation. **D.** Hybridization with whole chromosome 6 probe (Metasystem, Germany) showing translocation of chromosome 6 sequences to der(5) chromosome.

#### Other molecular cytogenetics technics

Fluorescence in situ hybridization (FISH) with LSI AML1-ETO, LSI MLL, LSI CBFβ/inv(16), LSI EGRI/5q31 (Abbott Molecular, Downers Grove, IL) and XL 6q21/6q23, XL PDGFR, whole chromosome 6 probe Metasystem, Germany).

#### Other molecular cytogenetics results

Normal signal patterns for LSI AML1-ETO, LSI MLL, LSI CBFβ/inv(16), LSI EGRI/5q31, XL 6q21/6q23 and XL PDGFR probes.


## Comments

Chromosomal translocations involving 5q33 and 6q23 have been reported in only one patient with T-

ALL and an associated myeloproliferative neoplasm and C6ORF204/PDGFRB fusion (Chmielecki et al 2012).

While in this case, the chromosomal translocation appeared to be morphologically identical to our  $t(5;6)(q33-34;q23)$ , in our patient PDGFRB (5q32-33) is not rearranged and MYB (6q23) is not translocated to chromosome 5 as in a previously described case.

Due to the availability of tyrosine kinase inhibitors for PDGFRB rearranged disorders, our findings emphasize the importance of FISH in precise characterizing of chromosome rearrangements with 5q33-34 breakpoints, especially in suboptimal preparations.



**Figure 2.** A. Karyotype from blood cell from the time of relapse showing the t(5;6)(q33-34;q23) and a new anomaly t(7;10)(p22;q23). B. Partial karyotypes from blood and bone marrow showing the t(5;6)(q33-34;q23).

## References

Chmielecki J, Peifer M, Viale A, Hutchinson K, Giltane J, Socci ND, Hollis CJ, Dean RS, Yenamandra A, Jagasia M, Kim AS, Davé UP, Thomas RK, Pao W. Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. *Genes*

*Chromosomes Cancer*. 2012 Jan;51(1):54-65

*This article should be referenced as such:*

Zamecnikova A, Al Bahar S, Pandita R. Translocation t(5;6)(q33-34;q23) in an acute myelomonocytic leukemia patient. *Atlas Genet Cytogenet Oncol Haematol*. 2014; 18(9):701-703.